Sign In
Buy PDSB
$1.08
-0.0800 (-6.90%)
At Close: Jun 03, 2026
PDS Biotechnology: Late-Stage Biotech With Enormous Potential
01:15pm, Wednesday, 26'th Apr 2023
PDS Biotechnology: Late-Stage Biotech With Enormous Potential.
PDS Biotechnology Corporation (PDSB) Q4 2022 Earnings Call Transcript
03:03pm, Tuesday, 28'th Mar 2023
PDS Biotechnology Corporation (NASDAQ:PDSB ) Q4 2022 Results Earnings Conference Call March 28, 2023 8:00 AM ET Company Participants Gabrielle DeGravina - Investor Relations, CG Capital Frank Bedu-Add
5 Best and Worst Performing Small-Cap Stocks in Q4 2022
10:53pm, Thursday, 26'th Jan 2023
The fourth quarter of 2022 was relatively better for the stock markets, with the S&P 500 up over 7% (its only positive quarterly return for the year).
PDS Biotech (PDSB) Up on Data From HPV-Positive Cancer Study
12:02pm, Thursday, 29'th Dec 2022
A mid-stage study data shows that treatment with PDS Biotech's (PDSB) lead candidate in advanced HPV-positive cancer patients achieved a median overall survival of 21 months.
PDS Biotechnology's latest trial reports improved survival in advanced cancer patients
11:19am, Wednesday, 28'th Dec 2022
PDS Biotechnology Corporation (NASDAQ:PDSB), a clinical-stage immunotherapy company owned by NetScientific, has reported expanded interim data from a Phase-2 clinical trial of its PDS0101 triple combi
PDS Biotechnology Corporation (PDSB) Q3 2022 Earnings Call Transcript
12:45pm, Monday, 14'th Nov 2022
PDS Biotechnology Corporation (NASDAQ:PDSB ) Q3 2022 Results Conference Call November 14, 2022 8:00 AM ET Company Participants Gabrielle DeGravina - Investor Relations, CG Capital Frank Bedu-Addo - Ch
PDS Biotech: Strong Data Indicate Further Upside
02:27am, Monday, 24'th Oct 2022
As it successfully pivoted into immuno-oncology, PDS is making big waves in this therapeutic development space. The premier drug development platform (Versamune) already generated extremely robust ear
Netsceintific pleased with progress at PDS Biotech
02:53am, Tuesday, 09'th Aug 2022
Netscientific PLC said it was encouraged by the progress being made at PDS Biotech after the US portfolio company released second-quarter results yesterday. Ilian Iliev, NetScientific's CEO, added: "W
PDS Biotechnology Corporation (PDSB) CEO Frank Bedu-Addo on Q2 2022 Results - Earnings Call Transcript
02:23pm, Monday, 08'th Aug 2022
PDS Biotechnology Corporation (NASDAQ:PDSB ) Q2 2022 Results Earnings Conference Call August 8, 2022 8:00 AM ET Company Participants Gabrielle DeGravina - Investor Relations, CG Capital Frank Bedu-Add
PDS Biotechnology Gains On FDA Fast Track Designation For Lead Candidate
10:57am, Thursday, 02'nd Jun 2022
The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to PDS Biotechnology's (NASDAQ: PDSB) lead drug candidate PDS0101 in combination with KEYTRUDA (pembrolizumab) for the t
PDS Biotechnology: Speculative Biotech Worth Buying After Latest Data
01:36pm, Friday, 27'th May 2022
Positive results were announced from the phase 2 NCI-led PDS0101 triple-combination study in patients with HPV16+ cancers; both CPI naive and CPI refractory patients were helped. Positive results were
PDS Biotech to Participate at Upcoming Investor Conferences
08:00am, Tuesday, 17'th May 2022
FLORHAM PARK, N.J., May 17, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer i
NetSceintific highlights PDS Biotech's key posters at upcoming ASCO conference
11:18am, Wednesday, 11'th May 2022
NetScientific PLC (AIM:NSCI) has noted first-quarter results from its portfolio company PDS Biotechnology, which also has results from key trials upcoming at the 2022 American Society of Clinical Onc
PDS Biotechnology Corporation (PDSB) CEO Frank Bedu-Addo on Q1 2022 Results - Earnings Call Transcript
11:15am, Wednesday, 11'th May 2022
PDS Biotechnology Corporation. (NASDAQ:PDSB ) Q1 2022 Earnings Conference Call May 11, 2022 8:00 AM ET Company Participants Gabrielle DeGravina - Investor Relations, CG Capital Frank Bedu-Addo - Chief
PDS Biotechnology Corporation (PDSB) CEO Frank Bedu-Addo on Q4 2021 Results - Earnings Call Transcript
12:34pm, Thursday, 31'st Mar 2022
PDS Biotechnology Corporation (PDSB) CEO Frank Bedu-Addo on Q4 2021 Results - Earnings Call Transcript
